UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults.
Chowdary P. et al, (2024), Haemophilia
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
Fischer K. et al, (2024), Research and Practice in Thrombosis and Haemostasis, 8
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
Madan B. et al, (2024), J Thromb Haemost
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Mitchell JL. et al, (2023), Platelets, 34
Frailty and haemophilia; speaking the language of geriatricians.
Sangha G. et al, (2023), Haemophilia, 29, 1371 - 1375
Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability
Mitchell JL. et al, (2023), Research and Practice in Thrombosis and Haemostasis, 7
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).
Wall C. et al, (2023), Haemophilia, 29, 743 - 752
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J. et al, (2023), N Engl J Med, 388, 694 - 705
Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
Zwagemaker A-F. et al, (2022), J Thromb Haemost
Safety and pharmacokinetic profile of apixaban in end‐stage renal disease: A real‐world analysis
Tseng CI. et al, (2022), eJHaem
GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements.
Dixon PH. et al, (2022), Nat Commun, 13
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P. et al, (2022), N Engl J Med, 387, 237 - 247
The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.
Whyte CS. et al, (2022), J Thromb Haemost
Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress.
Ariëns RA. et al, (2022), Res Pract Thromb Haemost, 6
The bleeding phenotype in people with non-severe hemophilia.
Kloosterman FR. et al, (2022), Blood Adv
Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England.
Higgins H. et al, (2022), Res Pract Thromb Haemost, 6
Cardiovascular disease in hereditary haemophilia: The challenges of longevity.
Shapiro S. et al, (2022), Br J Haematol